Withania somnifera water extract as a potential candidate for differentiation based therapy of human neuroblastomas
Kataria H, Wadhwa R, Kaul SC, Kaur G
PloS one · 25 citas
Etiquetas de revisión
Solo mecanismosDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Estudio in vitro o de mecanismos (clasificado por nuestro filtro de IA)
- Estudiado en
- Células o muestras de laboratorio
- Resultado principal
- Solo mecanismos
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Institute of Advanced Industrial Science and Technology
- Gobierno
- Department of Biotechnology, Ministry of Science and Technology, India
- Gobierno
- Council of Scientific and Industrial Research, India
Según 3 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2013-01-31 · PLoS One · vol. 8 · número 1 · pág. e55316
- Editorial
- Public Library of Science
- Citado
- 45 citas · más que el 98% de estudios similares · 14.6× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 82 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Phytochemicals and Medicinal Plants · Cell death mechanisms and regulation · Neuroblastoma Research and Treatments
- Palabras clave
- Withania somnifera, Neuroblastoma, Biology, Apoptosis, Cell cycle, Cancer research, Cell growth, Cellular differentiation, Cell biology, Medicine, Cell culture, Pathology, Biochemistry
- MeSH
- cell line, tumor, humans, withania, neuroblastoma, water, fluorescein-5-isothiocyanate, annexin a5, neural cell adhesion molecules, dna primers, plant extracts, blotting, western, phytotherapy, reverse transcriptase polymerase chain reaction, cell differentiation, cell proliferation, hsp70 heat-shock proteins, cell cycle checkpoints
4 autores
- Hardeep Kataria🇮🇳Guru Nanak Dev University
- Renu Wadhwa🇯🇵National Institute of Advanced Industrial Science and Technology
- Sunil C. Kaul🇯🇵National Institute of Advanced Industrial Science and Technology
- Gurcharan Kaur🇮🇳 · autor de correspondenciaGuru Nanak Dev University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Neuroblastoma is an aggressive childhood disease of the sympathetic nervous system. Treatments are often ineffective and have serious side effects. Conventional therapy of neuroblastoma includes the differentiation agents. Unlike chemo-radiotherapy, differentiation therapy shows minimal side effects on normal cells, because normal non-malignant cells are already differentiated. Keeping in view the limited toxicity of Withania somnifera (Ashwagandha), the current study was aimed to investigate the efficacy of Ashwagandha water extract (ASH-WEX) for anti-proliferative potential in neuroblastoma and its underlying signalling mechanisms. ASH-WEX significantly reduced cell proliferation and induced cell differentiation as indicated by morphological changes and NF200 expression in human IMR-32 neuroblastoma cells. The induction of differentiation was accompanied by HSP70 and mortalin induction as well as pancytoplasmic translocation of the mortalin in ASH-WEX treated cells. Furthermore, the ASH-WEX treatment lead to induction of neural cell adhesion molecule (NCAM) expression and reduction in its polysialylation, thus elucidating its anti-migratory potential, which was also supported by downregulation of MMP 2 and 9 activity. ASH-WEX treatment led to cell cycle arrest at G0/G1 phase and increase in early apoptotic population. Modulation of cell cycle marker Cyclin D1, anti-apoptotic marker bcl-xl and Akt-P provide evidence that ASH-WEX may prove to be a promising phytotherapeutic intervention in neuroblatoma related malignancies.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.